What Happened?
Shares of medical technology company Hologic (NASDAQ: HOLX) jumped 18.6% in the afternoon session after the Financial Times reported that private equity firms TPG and Blackstone made an offer to buy the company (HOLX).
Follow-up reports indicated that Hologic declined the offers, which valued the company at over $16 billion ($70–$72 per share), about a 30 percent premium to the prior day's close.
Still, the reports revealed that the deal could be revived, leaving open the prospect of a substantially higher exit price for current shareholders.
Is now the time to buy Hologic? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Hologic’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Hologic and indicate this news significantly impacted the market’s perception of the business.
Hologic is down 13.7% since the beginning of the year, and at $61.93 per share, it is trading 26% below its 52-week high of $83.72 from November 2024. Investors who bought $1,000 worth of Hologic’s shares 5 years ago would now be looking at an investment worth $1,205.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
